andyturbo
Administrator: PR.net
- Joined
- Dec 12, 2006
- Messages
- 4,395
![pubmed.ncbi.nlm.nih.gov](/community/proxy.php?image=https%3A%2F%2Fcdn.ncbi.nlm.nih.gov%2Fpubmed%2Fpersistent%2Fpubmed-meta-image-v2.jpg&hash=60139e87a9c8640158d1b284c92d97fa&return_error=1)
3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review - PubMed
The Food and Drug Administration (FDA) granted breakthrough therapy status to 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) in 2017 due to preliminary evidence supporting its efficacy and safety in treating post-traumatic stress disorder (PTSD). A series of six phase-II clinical tri …
![pubmed.ncbi.nlm.nih.gov](/community/proxy.php?image=https%3A%2F%2Fcdn.ncbi.nlm.nih.gov%2Fcoreutils%2Fnwds%2Fimg%2Ffavicons%2Ffavicon.png&hash=38a93253fc15d6430d52f4a6d11ea7d5&return_error=1)
MDMA is being fast-tracked for potential FDA approval by 2023. 67% of patients who participated in 3 MDMA-assisted therapy sessions no longer met the criteria for PTSD. The effects are durable for at least four years but could last even longer.